Fragile X syndrome is the most frequent cause of intellectual disability in males, affecting 1 out of 3600 boys born. For the first time, researchers at Whitehead Institute have restored activity to the fragile X syndrome gene in affected neurons using a modified CRISPR/Cas9 system they developed that removes the methylation—the molecular tags that keep the mutant gene shut off—suggesting that this method may prove to be a useful paradigm for targeting diseases caused by abnormal methylation.
Research by the lab of Whitehead Institute Founding Member Rudolf Jaenisch, which is described online this week in the journal Cell, is the first direct evidence that removing the methylation from a specific segment within the FMR1 locus can reactivate the gene and rescue fragile X syndrome neurons.
The FMR1 gene sequence includes a series of three nucleotide (CGG) repeats, and the length of these repeats determines whether or not a person will develop fragile X syndrome: A normal version of the gene contains anywhere from 5-55 CGG repeats; versions with 56-200 repeats are considered to be at a higher risk of generating some of the syndrome’s symptoms; and those versions with more than 200 repeats will produce fragile X syndrome.
Until now, the mechanism linking the excessive repeats in FMR1 to fragile X syndrome was not well understood. But Shawn Liu, a postdoctoral researcher in Jaenisch’s lab and first author of the Cellstudy, and others thought that the methylation blanketing those nucleotide repeats might play an important role in shutting down the gene’s expression.
In order to test this hypothesis, Liu removed the methylation tags from the FMR1 repeats using a CRISPR/Cas9-based technique recently developed by him and Hao Wu, a former postdoctoral researcher in the Jaenisch lab. This technique can either add or delete methylation tags from specific stretches of DNA. Removal of the tags revived the FMR1 gene’s expression to the level of the normal gene.
“These results are quite surprising—this work produced almost a full restoration of wild type expression levels of the FMR1 gene,” says Jaenisch, who is a professor of biology at Massachusetts Institute of Technology and the senior author on the study. “Often when scientists test therapeutic interventions, they only achieve partial restoration, so these results are substantial.”
The reactivated FMR1 gene rescues neurons derived from fragile X syndrome induced pluripotent stem (iPS) cells, reversing the abnormal electrical activity associated with the syndrome. When rescued neurons were engrafted into the brains of mice, the FMR1 gene remained active in the neurons for at least three months, suggesting that the corrected methylation may be sustainable in the animal.
“We showed that this disorder is reversible at the neuron level,” says Liu. “When we removed methylation of CGG repeats in the neurons derived from fragile X syndrome iPS cells, we achieved full activation of FMR1.”
The CRISPR/Cas-9-based technique may also prove useful for other diseases caused by abnormal methylation including facioscapulohumeral muscular dystrophy and imprinting diseases.
“This work validates the approach of targeting the methylation on genes, and it will be a paradigm for scientists to follow this approach for other diseases,” says Jaenisch.
The Latest on: Fragile X syndrome
via Google News
The Latest on: Fragile X syndrome
- Ovid Therapeutics to Present at the American Academy of Neurology 71st Annual Meeting on April 18, 2019 at 5:00 am
Ovid’s presentations on Angelman syndrome and Fragile X syndrome are part of the program at the 71st annual meeting of the American Academy of Neurology (AAN) in Philadelphia (May 4 - 10). The ... […]
- Computer-based memory games may be beneficial for individuals with fragile X syndrome on April 16, 2019 at 7:17 am
In the largest non-pharmacological trial ever in children with fragile X syndrome (FXS), UC Davis researchers found that large-scale, in-home cognitive interventions are feasible and may be beneficial ... […]
- Confluence Pharmaceuticals receives $200K investment from IU fund on April 15, 2019 at 12:29 pm
Confluence Pharmaceuticals CEO Steve Johns said the company is targeting its lead asset, a product for the treatment of fragile X syndrome to improve important functionality including ... […]
- Ovid Therapeutics (OVID) Lowered to Hold at Zacks Investment Research on April 13, 2019 at 4:18 am
The company’s product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved in developing OV935 in ... […]
- IU Fund Invests $200K in Autism Therapy on April 12, 2019 at 8:01 am
Confluence Pharmaceuticals develops what it describes as novel, clinically discovered, therapeutic treatments for core social and communication impairments related to fragile X syndrome and autism ... […]
- Altered steady state and activity-dependent de novo protein expression in fragile X syndrome on April 12, 2019 at 2:09 am
Whether fragile X mental retardation protein (FMRP) target mRNAs and neuronal activity contributing to elevated basal neuronal protein synthesis in fragile X syndrome (FXS) is unclear. Our proteomic ... […]
- Esperanza gives a special boy a special sendoff on April 12, 2019 at 12:35 am
Because the Ahwatukee youngster has Fragile X Syndrome – the leading genetic cause of developmental delays and autism – the boy was losing more than a nurturing environment where his mother, Sarah ... […]
- Clinical trial looking for children with Fragile X Syndrome to test treatment using CBD on April 8, 2019 at 8:40 pm
PHOENIX (FOX 10) -- Can CBD help certain autism patients? A local autism research center is hoping to experiment on patients, specifically with Fragile X Syndrome, a genetic condition that causes ... […]
- Novel Drug Promising for Life-Threatening Rett Syndrome in Kids on April 8, 2019 at 2:34 pm
In addition to RTT, trofinetide has been evaluated in phase 2 studies of traumatic brain injury and Fragile X syndrome. As an investigational drug, trofinetide has not yet been approved for use in any ... […]
- Queensland researchers study medicinal cannabis benefits on anxiety in Fragile X patients on April 8, 2019 at 7:00 am
QUEENSLAND researchers hope a medicinal cannabis gel trial for children with Fragile X syndrome will help relieve anxiety. Fragile X syndrome is the most common inherited form of intellectual ... […]
via Bing News